financetom
Business
financetom
/
Business
/
Geron's blood disorder drug gets FDA advisers' backing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Geron's blood disorder drug gets FDA advisers' backing
Mar 14, 2024 12:44 PM

March 14 (Reuters) - Advisers to the U.S. Food and Drug

Administration on Thursday voted in favor of Geron's ( GERN )

blood disorder drug,

stating that, based on late-stage trial data, the benefits

outweigh treatment associated risks in patients.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mastercard's profit jumps on resilient consumer spending
Mastercard's profit jumps on resilient consumer spending
Jan 30, 2025
(Reuters) - Mastercard reported a higher fourth-quarter profit on Thursday as a resilient economy encouraged consumers to ramp up spending in the holiday season. The company's shares rose 3.7% to $569 in premarket trading. Spending continues to be underpinned by a solid labor market and wage growth that have spurred consumer confidence, while retailers also offered discounts to attract budget-conscious...
Marsh McLennan beats profit estimates on risk and insurance business strength
Marsh McLennan beats profit estimates on risk and insurance business strength
Jan 30, 2025
Jan 30 (Reuters) - Insurance brokerage and consulting company Marsh McLennan's ( MMC ) fourth-quarter profit beat Wall Street estimates on Thursday, as its risk and insurance business recorded strong growth. WHY IT'S IMPORTANT Insurers have consistently raised policy prices in recent years in response to losses from wars and natural catastrophes, along with inflationary pressures. The sector usually sees...
L3Harris forecasts upbeat annual sales on strong defense demand
L3Harris forecasts upbeat annual sales on strong defense demand
Jan 30, 2025
Jan 30 (Reuters) - L3Harris Technologies ( LHX ) forecast 2025 sales above estimates and posted higher-than-expected fourth-quarter results on Thursday, bolstered by strong demand for weapons due to higher defense spending amid global geopolitical tensions. Demand for arms and military equipment has ballooned as a result of the Russia-Ukraine war and ongoing conflicts in the Middle East, benefiting defense...
Sherwin-Williams forecasts annual profit below estimates on soft demand
Sherwin-Williams forecasts annual profit below estimates on soft demand
Jan 30, 2025
(Reuters) - Paint maker Sherwin-Williams ( SHW ) on Thursday forecast current-year adjusted profit below analysts' expectations, hurt by continued demand choppiness. We expect demand softness to persist in several end markets well into the second half of the year, if not into 2026, said CEO Heidi Petz. The company's shares were down 1.8% in premarket trading Factory activity in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved